Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Xolremdi Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.05.45

    Xolremdi (mavorixafor) Coverage for WHIM Syndrome

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.05.45 alerts

    Get alerted when Policy 05.05.45 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity criteria for Xolremdi in members age 12 years and older with WHIM syndrome.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyXolremdi (mavorixafor) Coverage for WHIM Syndrome
    Policy CodePolicy 05.05.45
    Change TypeNo material clinical or coverage changes
    Effective DateDecember 20, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit the required clinical documentation for initial or continuation prior authorization requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12+Minimum age
    <400 cells/µLBaseline ANC
    6 monthsInitial authorization
    12 monthsContinuation authorization
    120/30 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Quantity limit
    Immunologist or hematologistPrescriber specialty

    Coverage Criteria

    Initial Therapy

    Authorization of 6 months may be granted to members 12 years of age and older for treatment of WHIM syndrome when all of the following criteria are met:

    ALL of the following

    • Member is 12 years of age or older.
    • Diagnosis of WHIM syndrome with a genotype-confirmed variant of the CXCR4 gene consistent with WHIM syndrome.
    • Baseline absolute neutrophil count (ANC) is less than 400 cells/µL.
    • Clinical manifestations of disease are consistent with WHIM syndrome, such as repeated bacterial infections or persistent warts.

    Continuation Therapy

    Authorization of 12 months may be granted for continued treatment in members requesting reauthorization and demonstrating a positive response to therapy based on any of the following:

    ALL of the following

    • Member is requesting reauthorization for continued treatment.
    • ANY of the following

      • Reduced infection frequency relative to pretreatment.
      • Reduction of warts on the skin and genital warts.
      • Increased absolute neutrophil count (ANC) and/or absolute lymphocyte count (ALC) relative to baseline.

    Xolremdi (mavorixafor) is considered not medically necessary for members who do not meet the criteria set forth above.

    Members currently receiving the requested medication as samples or through the manufacturer's patient assistance program will be required to meet the criteria for initial approval. This ensures that members are treated equally regardless of their provider's ability to access medication samples.

    Quantity and Clinical Coding Details

    Baseline absolute neutrophil count
    Required thresholdBaseline ANC must be less than 400 cells/µL.
    Eligibility useThe baseline ANC threshold is required for initial authorization.
    Initial authorizationAuthorization may be granted for 6 months when all criteria are met.
    Xolremdi quantity limit
    Standard limit120 capsules per 30 days.
    ProductXolremdi (mavorixafor) 100 mg capsules.
    FDA-recommended dosingWeight over 50 kg: 400 mg orally once daily; weight under 50 kg: 300 mg orally once daily.

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required to initiate coverage review for Xolremdi® (mavorixafor). Submit the required clinical documentation with the request.

    Documentation Required

    Initial-Request Documentation

    For an initial request, submit chart notes or medical records documenting all of the following: WHIM syndrome confirmed by a CXCR4 genotype variant, baseline absolute neutrophil count (ANC), and symptoms and complications associated with WHIM syndrome.

    • Diagnosis of WHIM syndrome confirmed by genotype variant of CXCR4
    • Baseline absolute neutrophil count (ANC)
    • Symptoms and complications associated with WHIM syndrome

    Disease Background

    WHIM syndrome is an ultra-rare combined primary immunodeficiency associated with warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. Genetic variants in the CXCR4 receptor impair movement of neutrophils and lymphocytes into the bloodstream, predisposing affected individuals to recurrent infections and warts. Xolremdi is indicated for patients 12 years of age and older with WHIM syndrome to increase circulating mature neutrophils and lymphocytes.

    Definitions and Clinical Measures

    WHIM syndrome
    Expanded nameWarts, hypogammaglobulinemia, infections and myelokathexis syndrome.
    DefinitionAn ultra-rare combined primary immunodeficiency.
    Genetic associationAssociated with genetic variants in the CXCR4 receptor or gene.
    Myelokathexis
    DefinitionFailure of neutrophils to move from the bone marrow into the bloodstream.
    Affected cellsNeutrophils, a type of white blood cell, are retained in the bone marrow.
    Relationship to WHIM

    Initial Authorization

    Initial Authorization

    Authorization of 6 months may be granted to members age 12 years and older for treatment of WHIM syndrome when all of the following criteria are met:

    Initial authorization

    • Age: Member is 12 years of age or older.age >=12 years
    • Genotype-confirmed diagnosis: Diagnosis of WHIM syndrome is confirmed by a genotype-confirmed variant of the CXCR4 gene consistent with WHIM syndrome.
    • Baseline neutropenia: Baseline absolute neutrophil count is less than 400 cells/µL.ANC <400 cells/µL

    Continuation Authorization

    Continuation Authorization

    Authorization of 12 months may be granted for continued treatment when the member demonstrates a positive response to therapy based on any of the following:

    Positive response to Xolremdi

    • Reduced infection frequency: Infection frequency is reduced relative to pretreatment.
    • Reduction of warts: Warts on the skin and/or genital warts are reduced.
    • Increased ANC or ALC: Absolute neutrophil count and/or absolute lymphocyte count has increased relative to baseline.ANC and/or ALC increased relative to baseline

    Quantity Limits

    Xolremdi (mavorixafor) 100 mg capsule
    MedicationXolremdi (mavorixafor) 100 mg capsule.
    Quantity limit120 capsules.
    Limit periodPer 30 days.
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyXolremdi (mavorixafor) Coverage for WHIM Syndrome
    Policy CodePolicy 05.05.45
    Change TypeNo material clinical or coverage changes
    Effective DateDecember 20, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit the required clinical documentation for initial or continuation prior authorization requests.
    SourceLink
    On This Page
    Coverage CriteriaQuantity and Clinical Coding DetailsPrior Authorization and DocumentationDisease BackgroundDefinitions and Clinical MeasuresInitial AuthorizationContinuation AuthorizationQuantity Limits
    Documentation Required

    Continuation Documentation

    For a continuation request, submit chart notes, laboratory values, or other medical records documenting disease stability or improvement.

    • Disease stability or improvement
    Note

    Specialist Involvement

    The requested medication must be prescribed by or in consultation with an immunologist or hematologist.

    • Immunologist
    • Hematologist
    Denial Risk

    Failure to Meet Coverage Criteria

    Xolremdi® (mavorixafor) is considered not medically necessary when the member does not meet the coverage criteria. Members currently receiving the medication as samples or through the manufacturer’s patient assistance program must still meet the criteria for initial approval.

    • Coverage criteria must be met for approval.
    • Current receipt through samples or the manufacturer’s patient assistance program does not waive the initial-approval criteria.
    Myelokathexis is one of the features included in WHIM syndrome.
    ANC
    Full termAbsolute neutrophil count.
    Initial eligibilityBaseline ANC must be less than 400 cells/µL for initial authorization.
    Continuation responseAn increase in ANC relative to baseline may demonstrate a positive response to therapy.
    ALC
    Full termAbsolute lymphocyte count.
    Continuation responseAn increase in ALC relative to baseline may demonstrate a positive response to continued therapy.
    Response assessmentIncreased ALC and/or ANC is one of the accepted criteria for reauthorization.
  1. Clinical manifestations of disease are consistent with WHIM syndrome, such as repeated bacterial infections or persistent warts.

    Examples are not exhaustive.